SCHEMBL2945159

SCHEMBL2945159

CCOC(=O)c1cc2c(cn1)c(Cc1cc(F)c(F)c(F)c1O)cn2CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CNR2 P34972 1/20 0.36
GABRA1 P14867 7/20 0.35
GABRG2 P18507 7/20 0.35
GABRB3 P28472 7/20 0.35
GABRA5 P31644 7/20 0.35
GABRA3 P34903 7/20 0.35
GABRA2 P47869 7/20 0.35
GABRA4 P48169 7/20 0.35
GABRA6 Q16445 7/20 0.35
GABRP O00591 6/20 0.35
GABRD O14764 6/20 0.35
GABRB1 P18505 6/20 0.35
GABRB2 P47870 6/20 0.35
GABRE P78334 6/20 0.35
GABRG1 Q8N1C3 6/20 0.35
GABRG3 Q99928 6/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945832 0.89 KDM4E (0.36) KDM4EALDH1A1HPGDHSD17B10CNR2
SCHEMBL2945330 0.87 MAP3K5 (0.35) KMT2AMAP3K5
SCHEMBL2951250 0.85 POLB (0.38) KDM4EALDH1A1HPGDHSD17B10CNR2
SCHEMBL2943196 0.83 LMNA (0.41) KDM4EALDH1A1HPGDHSD17B10CNR2
SCHEMBL2946990 0.81 GABRA1 (0.46) KDM4EALDH1A1HPGDHSD17B10CNR2
SCHEMBL2945079 0.80 ALOX5 (0.39) KDM4EALDH1A1CNR2GABRA1GABRG2
SCHEMBL2951309 0.80 GABRA1 (0.41) KDM4EALDH1A1HPGDHSD17B10CNR2
SCHEMBL2947275 0.79 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10CNR2
SCHEMBL4906425 0.79 NPC1 (0.38) KDM4EALDH1A1HPGDHSD17B10GABRA1
SCHEMBL2947278 0.78 GABRA1 (0.40) KDM4EALDH1A1HPGDHSD17B10CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558611-B1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER (US) 2010-01-06 EP disclosed
US-20080221154-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER INC 2008-09-11 US disclosed
US-7368571-B2 HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use PFIZER INC (US) 2008-05-06 US disclosed
US-20070004768-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-7135482-B2 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-11-14 US disclosed
US-20040147547-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147547-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use IMPDH1, POLA1, POLB KDM4E 1173/4885ALDH1A1 794/4885HPGD 185/4885
US-20070004768-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE TYMP, IMPDH1, POLB KDM4E 1098/4885ALDH1A1 1133/4885HPGD 107/4885
US-20080221154-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE TYMP, IMPDH1, POLB KDM4E 1001/4885ALDH1A1 1208/4885HPGD 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.